Recombinant COVID-19 Nucleocapsid Protein MBS8309646 from MyBioSource.com | Biocompare.com

Be the first to write a review!

Citations:

Supplier Page from
MyBioSource.com for
Recombinant COVID-19 Nucleocapsid Protein

Description

Recombinant COVID-19 Nucleocapsid Protein is produced by E.coli expression system and the target gene encoding Met1-Ala419 is expressed with a 6His tag at the N-terminus

Product Specs
ItemRecombinant COVID-19 Nucleocapsid Protein
CompanyMyBioSource.com
Price Supplier Page View Company Product Page
Catalog NumberMBS8309646
Source/Expression SystemE Coli
Size0.05 mg
FormatLiquid in a 0.2 ?m filtered solution of 20 mM Tris-HCl, 300 mM NaCl, 10 % glycerol, 1mM EDTA, pH 8.0
PurityGreater than 95% as determined by reducing SDS-PAGE
ApplicationsELISA (EIA), Western Blot (WB), SDS-Page
TypeRecombinant Protein
Molecule NameSARS-CoV-2 Nucleocapsid (2019-nCoV/Coronavirus)

Add to Compare List

MyBioSource.com

MyBioSource.com

P.O. Box 153308

San Diego, California

United States

Phone: 1-888-627-0165 (toll free) or 1-858-633-0165
Fax: 1-858-633-0166

Email: sales@mybiosource.com

Company Profile

Website: http://www.MyBioSource.com

(1) Production and characterization of a chimeric antigen, based on nucleocapsid of SARS-CoV-2 fused to the extracellular domain of human CD154 in HEK-293 cells as a vaccine candidate against COVID-19PLOS ONESeptember 26, 2023Thailin Lao, Ileanet Avalos, Elsa María Rodríguez, Yasser Zamora, Alianet Rodriguez, Ailyn Ramón, Yanitza Alvarez, Ania Cabrales, Ivan Andújar, Luis Javier González, et al.staining [16]. N-CD protein and SARS-CoV-2 N protein expressed in E. coli (MyBiosource, San Diego, USA, MBS8309646) were added in triplicate at a final concentration of 100 μg/ml. The antitumoral drug CIGB-300 (100

Be the First to Write a Review!